By Kelly Cloonan
Crispr Therapeutics said it is partnering with Sirius Therapeutics to develop and commercialize SRSD107, a small interfering RNA therapy to treat thromboembolic disorders.
Under the agreement, Crispr will make an upfront payment of $25 million in cash and $70 million in equity to Sirius Therapeutics, the companies said Monday.
The companies will jointly develop SRSD107 under an equally split cost and profit-sharing structure, they said. Crispr will lead commercialization in the U.S., while Sirius will be responsible for commercialization in China.
Crispr will also be able to nominate up to two siRNA targets for research and development, for which it would retain opt-in rights to lead commercialization, the companies said. Sirius will be eligible to receive milestone payments as well as tiered royalties in high single to low-double digits.
SRSD107 aims to selectively inhibit Factor XI, a driver of pathological thrombosis, in order to reduce thrombotic events and minimize the risk of bleeding. Two Phase 1 trials of the treatment have found it to be safe and well-tolerated, the companies said.
The collaboration expands Crispr's portfolio to develop a broader range of gene-based medicines in addition to its gene-editing programs, the companies said.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
May 19, 2025 16:44 ET (20:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。